A few recent Campaign updates from Treatment Action Group and allies.
Contact [email protected] for more information on how to be part of the 1/4/6x24 Campaign.

Advocates urge Johnson & Johnson to correct its course and stop blocking entry of generic versions of bedaquiline into the global market and into countries.

Médecins Sans Frontières urges the Indian Patent Office to reject the secondary patent application filed by Johnson & Johnson to prevent the company from extending its monopoly on bedaquiline beyond the primary patent’s expiry in July 2023.

Research led by The Union has found that it is feasible to incorporate contact investigation within national tuberculosis (TB) programmes in African countries.

The 1/4/6x24 (one, four, six by 2024) campaign calls for TB patients to have access to evidence-based, long-awaited, shorter, less toxic treatment. But without mass availability of drugs, can India afford to adopt the protocol, ask experts.

Researchers found high rates of tuberculosis among high-risk patients who sought care at primary health care clinics, many of whom had no preceding symptoms suggesting a high rate of subclinical TB.

Truenat MTB-INH is also expected to play a major role internationally, in high TB burden countries as well as countries that already have a policy in place for INH testing on all TB-positive samples, it claimed.

Read More →